BridgeBio Oncology Therapeutics (BBOT), a California-based biotech company and Helix Acquisition Corp II, a special purpose acquisition company (SPAC) have entered a merger agreement.

The transaction is expected to provide access to capital to advance BBOT’s pipeline of cancer therapies targeting RAS and PI3Kα malignancies. The company will trade under the name BridgeBio Oncology Therapeutics.